Royalty Pharma (RPRX) Non Operating Income (2019 - 2026)
Royalty Pharma (RPRX) posted Non Operating Income of -$94.8 million for Q1 2026, down 191.92% sequentially from -$32.5 million in Q4 2025, and up 4.98% YoY from -$90.3 million in Q1 2025.
Royalty Pharma (RPRX) Non Operating Income (2019 - 2026) Analysis & Trends
Royalty Pharma has reported Non Operating Income for 8 years, with the latest figure at -$94.8 million in Q1 2026.
- Quarterly Non Operating Income rose 4.98% year-over-year to -$94.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$229.4 million (down 75.24% YoY) and the FY2025 annual result came in at -$235.3 million, down 713.32% from the prior year.
- Non Operating Income fell to -$94.8 million in Q1 2026 per RPRX's latest filing, from -$32.5 million in the prior quarter.
- Over five years, Non Operating Income peaked at $113.8 million in Q2 2022 and troughed at -$127.4 million in Q4 2022.
- A 5-year average of -$9.4 million and a median of -$27.2 million in 2024 frame the typical range for Non Operating Income.
- The sharpest annual moves came in 2024 and 2025: Non Operating Income soared 342.75% in 2024, then plunged 243.52% in 2025.
- Over 5 years, Non Operating Income stood at -$127.4 million in 2022, then jumped by 182.19% to $104.7 million in 2023, then slumped by 125.95% to -$27.2 million in 2024, then decreased by 19.53% to -$32.5 million in 2025, then sank by 191.92% to -$94.8 million in 2026.
- According to Business Quant data, Non Operating Income over the past three periods registered -$94.8 million, -$32.5 million, and $17.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -51.63 Mn |
| Mar 31, 2026 | -94.78 Mn |
| Dec 31, 2025 | -32.47 Mn |
| Sep 30, 2025 | 17.06 Mn |
| Jun 30, 2025 | -119.16 Mn |
| Mar 31, 2025 | -99.75 Mn |
| Dec 31, 2024 | -27.16 Mn |
| Sep 30, 2024 | 71.28 Mn |
| Jun 30, 2024 | -75.25 Mn |
| Mar 31, 2024 | 69.50 Mn |
| Dec 31, 2023 | 104.69 Mn |
| Sep 30, 2023 | -29.37 Mn |
| Jun 30, 2023 | 102.50 Mn |
| Mar 31, 2023 | 30.12 Mn |
| Dec 31, 2022 | -127.38 Mn |
| Sep 30, 2022 | 28.20 Mn |
| Jun 30, 2022 | 113.81 Mn |
| Mar 31, 2022 | -91.64 Mn |
| Dec 31, 2021 | -99.75 Mn |
| Sep 30, 2021 | -81.26 Mn |